Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DVA 
DaVita HealthCare Partners Inc (DVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: DVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $159.15
1 Year Target Price $159.15
| 1 | Strong Buy |
| 0 | Buy |
| 8 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.41% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.77B USD | Price to earnings Ratio 14.12 | 1Y Target Price 159.15 |
Price to earnings Ratio 14.12 | 1Y Target Price 159.15 | ||
Volume (30-day avg) 10 | Beta 1.11 | 52 Weeks Range 131.76 - 179.60 | Updated Date 07/1/2025 |
52 Weeks Range 131.76 - 179.60 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.63% | Operating Margin (TTM) 13.44% |
Management Effectiveness
Return on Assets (TTM) 7.04% | Return on Equity (TTM) 54.79% |
Valuation
Trailing PE 14.12 | Forward PE 13.24 | Enterprise Value 22574338650 | Price to Sales(TTM) 0.83 |
Enterprise Value 22574338650 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 1.74 | Enterprise Value to EBITDA 8.47 | Shares Outstanding 75577000 | Shares Floating 38082955 |
Shares Outstanding 75577000 | Shares Floating 38082955 | ||
Percent Insiders 49.51 | Percent Institutions 49.25 |
Analyst Ratings
Rating 3 | Target Price 159.15 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 8 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
DaVita HealthCare Partners Inc
Company Overview
History and Background
DaVita was founded in 1999, evolving from Medical Equities, Inc. Initially focused on dialysis services, it expanded through acquisitions to become a leading provider of kidney care globally. A significant milestone was its strategic focus on providing comprehensive kidney care services.
Core Business Areas
- Kidney Care Services: Provides dialysis services, including hemodialysis and peritoneal dialysis, as well as related services like vascular access management.
- Ancillary Services and Strategic Initiatives: Includes pharmacy services, integrated care programs, and other strategic initiatives related to kidney care.
Leadership and Structure
DaVita is led by a board of directors and an executive leadership team. The organizational structure is designed to support its network of dialysis centers and related businesses, fostering efficient operations and strategic growth.
Top Products and Market Share
Key Offerings
- 2023_Revenue_USD_millions: 11571.2
- Dialysis Services: DaVita's core offering, providing life-sustaining dialysis treatments to patients with chronic kidney failure. DaVita holds a significant market share in the US dialysis market. Competitors include Fresenius Medical Care and US Renal Care.
- Market Share (%): 37
- Vascular Access Services: Provides services for the creation and maintenance of vascular access for dialysis patients. Market share is related to overall dialysis market share. Competitors include Fresenius Medical Care and independent vascular access centers.
- Integrated Kidney Care: Offers integrated care programs aimed at slowing the progression of kidney disease and improving patient outcomes. Market Share estimated < 10% of total kidney care market. Competitors includes Somatus and Strive Health.
Market Dynamics
Industry Overview
The kidney care industry is driven by the increasing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD). It's a regulated industry with significant government reimbursement through Medicare.
Positioning
DaVita is a leading provider of kidney care services, holding a strong market position due to its extensive network of dialysis centers and integrated care programs. Competitive advantages include its scale, experience, and focus on patient care.
Total Addressable Market (TAM)
The global kidney dialysis market is estimated at over $95 billion USD and is expected to grow annually. DaVita is positioned to capitalize on this growth through its existing market share and expansion strategies.
Upturn SWOT Analysis
Strengths
- Large and established network of dialysis centers
- Strong brand recognition and reputation
- Expertise in providing quality dialysis care
- Integrated care programs
Weaknesses
- High dependence on government reimbursement
- Exposure to regulatory changes
- Operational challenges in managing a large network
- Legal liabilities
Opportunities
- Expanding into new geographic markets
- Developing innovative dialysis technologies
- Growing integrated care programs
- Acquiring smaller dialysis providers
Threats
- Changes in government reimbursement policies
- Increased competition from other dialysis providers
- Technological advancements that disrupt the industry
- Economic downturns that affect patient access to care
Competitors and Market Share
Key Competitors
- FMS
- USREN
- BSI
Competitive Landscape
DaVita's advantage lies in its larger scale and more extensive network compared to smaller competitors. DaVita is a stronger partner over many companies listed.
Major Acquisitions
Saranas
- Year: 2021
- Acquisition Price (USD millions): 27.4
- Strategic Rationale: This strategic acquisition helps DaVita Healthcare better care for patients with acute kidney injury (AKI) undergoing continuous renal replacement therapy (CRRT).
Growth Trajectory and Initiatives
Historical Growth: DaVita has achieved significant growth through acquisitions and organic expansion of its dialysis center network.
Future Projections: Analysts project continued growth in revenue and earnings, driven by increasing demand for dialysis services and expansion of integrated care programs.
Recent Initiatives: Recent initiatives include investments in new dialysis technologies, expansion of integrated care programs, and acquisitions of smaller dialysis providers.
Summary
DaVita is a major player in the kidney care industry, holding a leading market share. They have demonstrated consistent growth. DaVita's dependence on government reimbursement and regulatory environment is a key challenge. They are positioned for continued expansion through strategic initiatives and a dedication to quality patient care.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Presentations
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DaVita HealthCare Partners Inc
Exchange NYSE | Headquaters Denver, CO, United States | ||
IPO Launch date 1995-10-31 | CEO & Executive Director Mr. Javier J. Rodriguez | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 76000 | Website https://www.davita.com |
Full time employees 76000 | Website https://www.davita.com | ||
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.